Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience

Giulia Calabretto1,2,14, Enrico Attardi3,4,14, Antonella Teramo1,2, Valentina Trimarco1, Samuela Carraro1, Sandra Mossuto4, Gregorio Barilà1, Cristina Vicenzotto1,2, Vanessa Rebecca Gasparini1,2, Monica Crugnola4,6, Pasquale Niscola4,7, Antonella Poloni1,3,6, Valentina Giai1,9, Valentina Gaidano4,10, Carlo Finelli1,4,11, Roberta Bertorelle12, Cinzia Candiotto12, Marco Pizzi13, Gianni Binotto1,3, Monica Facco1,12, Fabrizio Vianello1, Livio Trentin1, Gianpietro Semenzato1,2, Renato Zambello1,2,4,14,15 and Valeria Santini1,4,8

© The Author(s) 2022, corrected Publication 2022

Leukemia (2022) 36:1947–1950; https://doi.org/10.1038/s41375-022-01592-3

TO THE EDITOR:
Myelodysplastic Syndromes (MDS) are a highly heterogeneous group of blood neoplasias characterized by myeloid dysplasia, ineffective hematopoiesis and increased risk of progression to acute myeloid leukemia [1]. We focused on hypocellular-MDS (h-MDS), a rare subtype accounting for 10–15% of MDS patients, that is defined by an age-adjusted reduction of bone marrow (BM) cellularity or, according to Aplastic Anemia definition, by a BM cellularity <30% [2].

Although the WHO classification of myeloid neoplasms and acute leukemia does not recognize h-MDS as a distinct entity, these patients are typically younger and characterized by more severe cytopenias, higher transfusion dependence and lower blast percentages as compared to normo/hypercellular MDS (n-MDS) [3–5]. Data on h-MDS outcome, instead, are still inconsistent [4, 6]. Beside these clinical features, h-MDS share molecular characteristics, including karyotype abnormalities, that suggest a common underlying pathogenesis [4, 5].

A barely understood biology, ill-defined diagnostic criteria and the lack of conclusive prognostic data hindered the establishment of specific treatment guidelines for h-MDS. The evaluation of clinical outcome following immunosuppressive therapy (IST) in MDS patients indicated peculiar responses in the hypoplastic category [7, 8], supporting a pathogenetic role of immune system alterations. In this regard, the immunological characterization of h-MDS should help to improve the risk stratification of patients and choice of therapy.

Taking advantage of the National Registry of the Italian Foundation of MDS (FISiM), we evaluated clinical features, overall survival (OS) and treatment of h-MDS in comparison with n-MDS. A cohort of 1945 MDS patients, enrolled in the FISiM registry, was included in the study. Patients were selected based on the availability of bone trephine biopsy evaluation and complete clinical annotations. Diagnosis of h-MDS was assumed for BM cellularity ≤30% and the prognostic stratification of patients was defined according to the Revised International Prognostic Scoring System (IPSS-R) [9].

Within the main cohort, 336/1945 (17%) patients were recognized as h-MDS and 1609/1945 (83%) as n-MDS. The age of patients ranged between 18 to 106 years, with a global M/F ratio of 1.56. According to BM cellularity, median age was 75 and 74 years in the h-MDS and n-MDS groups, respectively; the M/F ratio was 1.14 in h-MDS and 1.67 in n-MDS (p < 0.01).

The stratification of patients into IPSS-R risk categories was similar between h-MDS and n-MDS (Fig. 1A). An IPSS-R score of 3.5 was used to stratify patients into two main groups: low-risk IPSS-R (LR, score ≤3.5) and high-risk IPSS-R (HR, score >3.5). Accordingly, 271/336 (81%) h-MDS were placed in the LR and 65/336 (19%) in the HR categories; similarly, 1176/1609 (73%) of n-MDS were included in the LR, while 433/1609 (27%) in the HR groups.

Median OS was 77 months for h-MDS and 56 months for n-MDS (p = 0.05). According to IPSS-R stratification and BM cellularity, LR h-MDS had a median OS of 125 months, while LR n-MDS of 74 months (p = 0.001). Conversely, median OS in HR MDS was

1Hematology Division, Department of Medicine, Padua University School of Medicine, Padua, Italy. 2Veneto Institute of Molecular Medicine (VIMM), Padua, Italy. 3MDS Unit, Division of Hematology, AOI Careggi-University of Florence, Florence, Italy. 4Italian MDS Foundation (FISiM - ETS), Bologna, Italy. 5Hematology Unit, Ospedale dell’Angelo, Venezia-Mestre, Italy. 6Hematology Unit and BMT Center, AOI-Parma, Parma, Italy. 7Department of Hematology, S. Eugenio Hospital, Rome, Italy. 8Division of Hematology, AOU Ospedali Riuniti - Università Politecnica Marche, Ancona, Italy. 9Division of Hematology, Department of Oncology, AOI Città della Salute e della Scienza, Turin, Italy. 10Department of Hematology, AOSS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. 11IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy. 12Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-RIRCS, Padua, Italy. 13Department of Medicine, Surgical Pathology and Cytopathology Unit, University School of Medicine, Padua, Italy. 14These authors contributed equally: Giulia Calabretto, Enrico Attardi, Renato Zambello, Valeria Santini. 15email: r.zambello@unipd.it; valeria.santini@uni.it

Received: 4 December 2021 Revised: 3 May 2022 Accepted: 4 May 2022
Published online: 21 May 2022
Fig. 1  Risk stratification and OS of h-MDS compared to n-MDS. 1-A Patients stratification into IPSS-R risk categories. H-MDS are represented in shades of blue (with light blue stating for very low risk and dark blue stating for very high risk categories); n-MDS are represented in shades of green (with light green stating for very low risk and dark green stating for very high risk categories). In detail, h-MDS were distributed as follows: 15.5% Very Low, 35.1% Low, 30.1% Intermediate, 11.3% High, 8% Very High. N-MDS patients were classified as: 12.8% Very Low, 37.2% Low, 23.1% Intermediate, 15.5% High, 11.4% Very High. 1-B Kaplan–Meier curves showing OS in the entire MDS cohort (left panel), LR-MDS (central panel) and HR-MDS (right panel), comparing h-MDS (in blue) vs n-MDS (in green). Vertical lines denote censored patients. Median OS is significantly higher in LR h-MDS as compared to LR n-MDS (central panel, 125 vs 74 months, p < 0.001). Note: h-MDS, hypocellular myelodysplastic syndromes; HR high-risk; LR low-risk; n-MDS normo-/hypercellular myelodysplastic syndromes; OS overall survival.

comparable, i.e. 19 months in HR h-MDS patients vs 20 months in n-MDS cases (p > 0.05) (Fig. 1B).

Beyond its clinical relevance, our observations provide reliable data on h-MDS outcome, possibly clarifying previously reported inconsistencies [4, 10]. Most importantly, this evidence suggests that discrete biological features might account for the divergent course of the disease.

MDS are known to be characterized by a wide spectrum of immunological deregulations [1], including the frequent expansion of LGL clones, reaching the diagnostic criteria of LGL Leukemia (LGLL) in up to 27% of cases [11, 12]. This prompted us to better characterize the immunological landscape of h-MDS patients, at the time of diagnosis, focusing on cytotoxic T and NK cell subsets.

A restricted subgroup of 12 h-MDS patients was enrolled within the FISIM-MDS14 sub-study (Supplementary Table 1), to investigate the immune mechanisms in this peculiar disease subset. The study was approved by local ethic committees and patients signed informed consent, according to the Helsinki Declaration.

Immunophenotypic analysis was performed on both peripheral blood (PB) and BM samples. A CD3+/CD4−/CD8+/CD16+/CD56−/CD57+ cytotoxic T-LGL expansion was found in 8/12 (66%) cases in PB samples (range: 14–46% of lymphocytes) and in all the BM samples (range: 7–46% of lymphocytes), with respect to normal values (range: 6 ± 3% and 4 ± 2% of lymphocytes in PB and BM, respectively) (Supplementary Table 2). No recurrent TCR-Vβ immunodominant expansions were observed. To distinguish clonal from reactive expansions, TCR rearrangement was evaluated on DNA from PB and BM mononuclear cells (PBMC and BMMC). TCR clonality was demonstrated in 6/12 (50%) patients, with a concordance between PB and BM (Supplementary Table 2).

Noteworthy, the threshold commonly accepted for LGLL diagnosis (LGL > 0.5 × 10⁹/L) was reached only in 2/6 (33%) cases with a T cell clone, i.e. in the 17% of the h-MDS subgroup.

The immunophenotypic characterization of NK cell compartment showed CD3−/CD16bright/CD56dim/neg NK cell expansions in 4/12 (33%) h-MDS cases (range: 19–30% and 19–22% of lymphocytes in PB and BM, respectively), as compared to physiologic condition (range: 13 ± 5% and 6 ± 5% of lymphocytes in PB and BM, respectively) (Supplementary Table 2). NK cells were characterized by an effector-memory phenotype, based on the expression of CD57 and lack of CD62L. Evaluation of Killer Immunoglobulin-like receptors (KIR) confirmed a restricted pattern of expression, characterized by the prevalent expression of CD158b (i.e. KIR2DL2/L3) in all the 4 cases (range: 70–78% of CD3-CD16+ NK cells); of these, 3/4 (75%) were also characterized by the expression of the activating NKG2C receptor (Supplementary Table 2). As for clonal T cell proliferations, KIR restrictions in NK cell populations were detected both in PB and BM samples.

In line with previous reports, we observed that the immunological landscape of h-MDS patients is characterized by T and NK cell expansions [5, 13]. The novelty of our findings relies on the dominant involvement of different LGL subsets, according to patient prognostic stratification. In detail, 5/6 (83%) patients with a T-cell clone were included among the HR group, while only 1/6 (17%) was placed in the LR category. Conversely, 3/4 (75%) patients with a NK cell clonal expansion were included in the LR group, while 1/4 (25%) fell in the HR category (Fig. 2). Although our findings need to be confirmed in a larger number of cases, the observed immunological differences could be at the basis of the improved OS that we exclusively observed in the LR h-MDS group.

We previously reported the coexistence of T cell clones in ~50% of patients with chronic lymphoproliferative disorder of NK cells (CLPD-NK) [14]. In h-MDS patients, instead, no contemporary detection of TCR or KIR restriction was observed (Fig. 2), suggesting that T and NK clonal expansions may be mutually exclusive. This different involvement of T or NK cell subsets hints at distinct functional events taking place along h-MDS course, reminding the impairment of NK cell activity involved in n-MDS progression [1].

At a molecular level, we observed the presence of STAT3 activating mutations in PBMC and BMMC of 2/12 (17%) h-MDS cases (Supplementary Table 1). STAT3 mutated patients were those who fulfilled the diagnostic criteria of LGLL and they were both characterized by a monoclonal TCRαβ/CD3+/CD4−/CD8−/CD16+/CD56−/CD57+ T-LGL expansion and included in the HR group. Based on this evidence, STAT3 mutations might be associated with a worse prognosis with respect to STAT3 wild-
type cases, as in LGLL patients. Consistently, STAT3 mutated T cytotoxic clones may promote a chronic inflammatory BM environment and a persistent deregulated immune activation, leading to disease progression in a discrete subset of h-MDS cases. In line with this consideration, different hypotheses have been proposed to explain the peculiar association between LGL and myeloid clones. This is quite rare, possibly representing an extreme condition caused by common age-related pathogenetic mechanisms (i.e. a pro-inflammatory environment and mutational stress). Otherwise, LGLL may evolve from an immune surveillance reaction, with aberrant hematopoietic stem cells (HSC) triggering LGL activation and clonal expansion; on the contrary, clonal LGL might themselves promote a damage in the HSC compartment, leading to MDS development.

Beyond their pathogenetic role, the observed immune alterations may have relevant clinical implications, supporting the rationale for the administration of immunosuppressive agents. In our cohort, we observed that IST is rarely applied, irrespective of BM cellularity. In detail, immunosuppressive treatments were employed for 0.4% and 1.2% of LR h-MDS and n-MDS, respectively (Supplementary Table 3). Notwithstanding, our results in h-MDS suggest that treatment with immunosuppressive agents could be an effective strategy in this disease subset. Most importantly, the immunological features of h-MDS patients may be involved in the mechanism and duration of treatment responses.

In conclusion, we report an unbiased clinical analysis of the FISiM registry, based on the largest series of h-MDS (336 patients) so far evaluated, in comparison with an extended cohort of n-MDS. Of note, we showed a significant longer OS in LR h-MDS vs LR n-MDS.

In a preliminary investigation of h-MDS patients, combining phenotypic and molecular analyses, the LR group resulted to be characterized by KIR/NKG2 restricted NK cell expansions, whereas HR h-MDS were associated with T cell clones. Prospective studies are ongoing to better define the prognostic roles of the different LGL subsets in these patients. Remarkably, our observations might pave the way for the establishment of prospective trials to evaluate the efficacy of IST in h-MDS patients and the modulation of their T and NK cell repertoire.

REFERENCES

1. Cazzola M. Myelodysplastic Syndromes. N Engl J Med. 2020;383:1358–74.
2. Hasserjian RP, Orazi A, Brunning R, Germing U, Le Beau MM, Morosi C, et al. Myelodysplastic syndromes: overview. In: Swerdlow SH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon (France): IARC; 2017. 98–106.
3. Huang T-C, Ko B-S, Tang J-L, Hsu C, Chen C-Y, Tsay W, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia. 2008;22:544–50.
4. Bono E, McLorman D, Travaglino E, Ghidini S, Galli A, Khan AA, et al. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019;33:2495–505.
5. Fattizzo B, Serpenti F, Barcellini W, Caprioli C. Hypoplastic myelodysplastic syndromes: a genetic perspective. Cancers. 2021;13:132.
6. Tong W-G, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012;118:4662–70.
7. Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2:1765–72.
8. Stahl M, Bewersdorf JP, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica. 2020;105:102–11.
9. Greenberg PL, Teutebler H, Schanz S, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
10. Slaad EM. Hypocellular myelodysplasia. Hematol Oncol Clin North Am. 2009;23:347–60.
11. Durranli J, Awada H, Kishitgari A, Visconte V, Kerr C, Adema V, et al. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. Leukemia. 2020;34:957–62.
12. Komorikti RS, Alia N, Sallman D, Pedron E, Prasana L, Jezek J, et al. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. 2020;34:3097–9.
13. Karantanos T, DeZern AE. Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. Best Pract Res Clin Haematol. 2021;34:101280.
14. Gattazzo C, Teramo A, Passeri F, De March E, Carraro S, Traramico V, et al. Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. Haematologica. 2014;99:1826–33.
15. Barlà G, Talebian A, Calabretto G, Vicenzetto C, Gasparini VR, Pavan L, et al. Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. Leukemia. 2020;34:1116–24.

ACKNOWLEDGEMENTS

Part of this study was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, IG-20216 to GS). The authors would like to acknowledge the Italian Foundation of Myelodysplastic Syndromes (FISiM) and the project on rare diseases of the Department of Medicine (DIMAR) at the University of Padova.

AUTHOR CONTRIBUTIONS

RZ, VS conceived the study. GC, VT, SC, CV performed flow cytometric analyses. GC, AT, VRG, RB, CC performed mutational analyses. EA, SM, GBa, MC, PN, AP, VGi, VGa, CF, MF, GB, MF, PV, LT, RZ, VS provided patient and clinical data. GC, EA, RZ, VS wrote the manuscript. GS, RZ, VS critically edited the manuscript. GS provided funding. All the authors read and approved the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.
ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41375-022-01592-3.

Correspondence and requests for materials should be addressed to Renato Zambello or Valeria Santini.

Reprints and permission information is available at http://www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected Publication 2022